Japanese journal of clinical oncology最新文献_第4页

Population-based claims study of regional and hospital function differences in opioid prescribing for cancer patients who died in hospital in Japan. 日本医院死亡癌症患者阿片类药物处方区域和医院功能差异的人群索赔研究

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-22 DOI: 10.1093/jjco/hyaf149

Richi Takahashi, Mitsunori Miyashita, Yoko Nakazawa, Saho Wada, Yutaka Matsuoka

{"title":"Population-based claims study of regional and hospital function differences in opioid prescribing for cancer patients who died in hospital in Japan.","authors":"Richi Takahashi, Mitsunori Miyashita, Yoko Nakazawa, Saho Wada, Yutaka Matsuoka","doi":"10.1093/jjco/hyaf149","DOIUrl":"https://doi.org/10.1093/jjco/hyaf149","url":null,"abstract":"Background: Opioids are essential for cancer pain; however, regional and hospital prescribing variations in Japan remain poorly understood. This study aimed to investigate the regional and hospital functional differences in opioid prescribing among terminally ill patients with cancer in Japan using nationwide claims data.Methods: We analysed anonymized claims data from the DeSC database, focusing on patients who died of cancer in hospitals (2018-2022). We calculated opioid prescription prevalence and mean daily doses (converted to oral morphine equivalents) in the last 30 days of life. Outcomes were compared across regions and hospital functions using multivariate logistic and linear regression models adjusted for age, sex, and cancer type.Results: We analysed 119 850 decedents. Oxycodone injection use was highest in Tokai (16.4%) and South Kanto (15.7%), approximately four times that in Shikoku (4.0%). Transdermal fentanyl use ranged from 51.5% in Kyushu/Okinawa to 25.4% in South Kanto. Oxycodone injections increased with hospital functionality (4.1% in non-acute care vs. 20.4% in university hospitals), whereas transdermal fentanyl use declined (56.7%-13.1%). Compared to South Kanto, adjusted odds ratios (ORs) for opioid prescribing were higher in Kyushu/Okinawa (1.29) and lower in Kinki (0.68). For dose, no region exceeded South Kanto, and the lowest geometric mean ratio (GMR) was observed in Shikoku (0.87). No significant differences in adjusted ORs or GMRs were observed across hospital categories.Conclusion: Opioid prescribing patterns varied across regions and hospital functions, with significant differences in both prevalence and dosing. These findings may contribute to advancing the uniform implementation of palliative care.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic body radiotherapy for lung cancer: a review. 立体定向放疗治疗肺癌的研究进展。

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-18 DOI: 10.1093/jjco/hyaf142

Yasushi Nagata, Tomoki Kimura

引用次数: 0

Insulin-like growth factor-binding protein 3 and incidence of pancreatic cancer in a nested case-control study. 胰岛素样生长因子结合蛋白3与胰腺癌发病率的巢式病例对照研究

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-18 DOI: 10.1093/jjco/hyaf146

Yasushi Adachi, Masanori Nojima, Yingsong Lin, Yoshiharu Masaki, Yasushi Sasaki, Hiroshi Nakase, Kenji Wakai, Mitsuru Mori, Akiko Tamakoshi

{"title":"Insulin-like growth factor-binding protein 3 and incidence of pancreatic cancer in a nested case-control study.","authors":"Yasushi Adachi, Masanori Nojima, Yingsong Lin, Yoshiharu Masaki, Yasushi Sasaki, Hiroshi Nakase, Kenji Wakai, Mitsuru Mori, Akiko Tamakoshi","doi":"10.1093/jjco/hyaf146","DOIUrl":"https://doi.org/10.1093/jjco/hyaf146","url":null,"abstract":"Background: Insulin-like growth factors (IGFs) are potent mitogens and IGF-binding protein 3 (IGFBP3) can regulate IGF activity. To elucidate relationships between IGF-related molecules and risk of pancreatic cancer, we analyzed associations between serum levels of IGF1 and IGFBP3 and incidence of pancreatic cancer in a prospective, nested, case-control study within the Japan Collaborative Cohort study.Methods: A baseline survey was conducted from 1988 to 1990, during which period blood samples were obtained from 39 242 subjects. Subjects who had been diagnosed with pancreatic cancer by 1997 were regarded as cases. Conditional logistic regression was used to estimate odds ratios (ORs) for the incidence of pancreatic cancer in relation to serum levels of IGF1 and IGFBP3.Results: This analysis included 72 cases and 216 controls. Free IGFBP3 (estimated as IGFBP3-IGF1) was associated with the risk of pancreatic cancer (P for trends = 0.011), with the third tertile showing the highest risk (OR = 3.42, 95%CI = 1.31-8.91). None of total IGF1, free IGF1 (estimated as IGF1/IGFBP3), or total IGFBP3 were associated with risk of pancreatic cancer. This result remained unchanged in subanalyses of male, female, and older subjects (P for trends = 0.017, 0.030, and 0.007, respectively). When limiting analysis to participants followed for over 2 years, free IGFBP3 was associated with risk of pancreatic cancer (P for trends = 0.025).Conclusions: Our findings suggest that free IGFBP3 is associated with the risk of pancreatic cancer.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer treatment delay and 5-year mortality among patients diagnosed with common cancers from 2000 to 2017 in the Philippines. 2000年至2017年菲律宾常见癌症患者的癌症治疗延迟和5年死亡率

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-10 DOI: 10.1093/jjco/hyaf139

Jansen M Cambia, Edmund Cedric A Orlina, Gehan Alyanna C Calvez, Jason J Liu

{"title":"Cancer treatment delay and 5-year mortality among patients diagnosed with common cancers from 2000 to 2017 in the Philippines.","authors":"Jansen M Cambia, Edmund Cedric A Orlina, Gehan Alyanna C Calvez, Jason J Liu","doi":"10.1093/jjco/hyaf139","DOIUrl":"https://doi.org/10.1093/jjco/hyaf139","url":null,"abstract":"Objectives: Treatment delay can adversely affect cancer prognosis and public health. However, previous studies have not examined the association between cancer treatment delay and 5-year mortality risk for various cancer types in a single study population.Methods: We used retrospective cohort data from 21 740 patients diagnosed with common cancers between 2000 and 2017, with mortality follow-up to 2022, from the Philippines' Department of Health-Rizal Cancer Registry to understand how treatment delay of <30, 30-90, or >90 days was associated with 5-year all-cause mortality risk, by cancer type and stage at diagnosis. Poisson regression with robust variance was used to obtain the risk ratio and 95% confidence interval for the associations.Results: After adjusting for confounding, patients with treatment delays of more than 90 days had significantly higher 5-year mortality risk (risk ratio = 1.09; 95% confidence interval: 1.04-1.14) compared to those with delays of <30 days. Treatment delay was significantly associated with higher 5-year mortality in breast and cervical cancers, but not for the other cancer types (P-trend < .05). There was also a significant association between treatment delay and 5-year mortality of non-metastatic but not metastatic cancer at diagnosis (P-trend < .05).Conclusion: Our findings suggest that the 5-year prognosis of certain cancer types and non-metastatic cancer may be more adversely influenced by their delayed treatment, which will inform cancer control programs globally to reduce treatment delay and improve cancer prognosis.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients. 氨柔比星单药治疗老年难治性、复发性小细胞肺癌。

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-07 DOI: 10.1093/jjco/hyaf140

Masashi Takemoto, Shiori Kinoshita, Kazuki Yamada, Minami Asaoka, Yuji Hotta, Yoko Furukawa-Hibi, Takehiro Uemura, Hirokazu Komatsu

{"title":"Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients.","authors":"Masashi Takemoto, Shiori Kinoshita, Kazuki Yamada, Minami Asaoka, Yuji Hotta, Yoko Furukawa-Hibi, Takehiro Uemura, Hirokazu Komatsu","doi":"10.1093/jjco/hyaf140","DOIUrl":"https://doi.org/10.1093/jjco/hyaf140","url":null,"abstract":"Background: Amrubicin monotherapy has been used in Japan for patients with refractory, relapsed, small cell lung cancer (SCLC). However, the clinical guidelines do not specify a recommended initial dose for elderly patients. This retrospective study aimed to explore the appropriate initial dose of amrubicin for elderly patients with refractory, relapsed SCLC.Methods: This study included elderly patients (aged ≥70 years) with refractory, relapsed SCLC who received amrubicin monotherapy at Nagoya City University Hospital between April 2009 and March 2023. Patients were divided into two groups based on the initial dose: the low-dose group (<40 mg/m2) and the high-dose group (≥40 mg/m2).Results: Forty-seven patients were included, thirty-eight in the low-dose group and nine in the high-dose group. Median progression-free survival was significantly longer in the low-dose group than in the high-dose group (3.64 vs. 1.5 months, P = 0.04), whereas overall survival was not significantly different (10.18 vs. 8.18 months, P = 0.58). Febrile neutropenia occurred in seven patients. Treatment discontinuation due to adverse events was more frequent in the high-dose group (44.4%) than in the low-dose group (13.5%). Non-infectious adverse events such as interstitial pneumonia, arrhythmia, and myocardial infarction were observed in five patients who discontinued treatment.Conclusions: Both hematological and non-infectious adverse events may have contributed to shorter progression-free survival in the high-dose group. Low-dose administration, granulocyte colony-stimulating factor support, and close monitoring for non-infectious toxicities may be important in elderly patients.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence, risk factors, and prognostic impact of regional lymph node metastasis in bone sarcoma: a population-based cohort study. 骨肉瘤区域淋巴结转移的发病率、危险因素和预后影响：一项基于人群的队列研究。

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-05 DOI: 10.1093/jjco/hyaf096

Hiroshi Kobayashi, Liuzhe Zhang, Koichi Okajima, Yusuke Tsuda, Toshihiko Ando, Toshihide Hirai, Akira Kawai, Sakae Tanaka

{"title":"Incidence, risk factors, and prognostic impact of regional lymph node metastasis in bone sarcoma: a population-based cohort study.","authors":"Hiroshi Kobayashi, Liuzhe Zhang, Koichi Okajima, Yusuke Tsuda, Toshihiko Ando, Toshihide Hirai, Akira Kawai, Sakae Tanaka","doi":"10.1093/jjco/hyaf096","DOIUrl":"10.1093/jjco/hyaf096","url":null,"abstract":"Background: This study aimed to investigate the risk factors and prognostic impact of regional lymph node metastasis (RLNM) in patients with bone sarcoma.Methods: This retrospective study analyzed data from a Japanese registry of patients with bone sarcoma (2006-19). Disease-specific overall survival was estimated using the Kaplan-Meier method. A Cox regression model was used to identify risk factors for RLNM and prognostic factors.Results: Among 5064 patients, 157 (3.1%) had RLNM. The incidence varied by histological subtype: 7.6% in Ewing sarcoma, 3.1% in osteosarcoma, 1.6% in chondrosarcoma, and 5.2% in undifferentiated pleomorphic sarcoma. Higher rates were observed in rare subtypes, including mesenchymal chondrosarcoma (12.9%) and dedifferentiated chondrosarcomas (10.3%). Risk factors for RLNM included older age, tumor size (>8 cm) (P = .02), distant metastasis at diagnosis (P < .0001), skip metastasis (P < .0001), and histological subtype (e.g. Ewing sarcoma and dedifferentiated chondrosarcoma). RLNM was associated with poor prognosis (HR 1.69, 95% CI: 1.35-2.1, P < .0001), with isolated RLNM conferring survival outcomes equivalent to those with distant metastasis. Among RLNM cases, skip metastasis was the only significant independent predictor of poor prognosis (HR 2.41, 95% CI: 1.35-4.30, P = .003).Conclusions: The incidence of RLNM in bone sarcomas varies by histological subtype. Risk factors include older age, tumor size, distant metastasis, skip metastasis, and histological subtype. Isolated RLNM has a prognosis comparable to that of distant metastases, and skip metastasis is a significant negative prognostic factor.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1054-1061"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extended pelvic lymphadenectomy does not improve biochemical recurrence in high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a propensity-matched comparison of two institutions. 延长盆腔淋巴结切除术不能改善机器人辅助根治性前列腺切除术治疗的高危前列腺癌患者的生化复发：两家机构的倾向匹配比较。

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-05 DOI: 10.1093/jjco/hyaf100

Sohei Iwagami, Haruka Miyai, Takahito Wakamiya, Shimpei Yamashita, Masaya Nishihata, Isao Hara, Yasuo Kohjimoto

{"title":"Extended pelvic lymphadenectomy does not improve biochemical recurrence in high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a propensity-matched comparison of two institutions.","authors":"Sohei Iwagami, Haruka Miyai, Takahito Wakamiya, Shimpei Yamashita, Masaya Nishihata, Isao Hara, Yasuo Kohjimoto","doi":"10.1093/jjco/hyaf100","DOIUrl":"10.1093/jjco/hyaf100","url":null,"abstract":"Background: Pelvic lymph node dissection in intermediate- or high-risk localized prostate cancer is important for detecting or eliminating lymph node metastases. This study evaluates the effectiveness of extended pelvic lymph node dissection (ePLND) for high-risk prostate cancer.Methods: We identified 275 patients who underwent robot-assisted radical prostatectomy for high- or very high-risk prostate cancer, as defined by the National Comprehensive Cancer Network risk categories, at two centers between May 2013 and March 2021. Using propensity score matching, 61 patients from each group were compared between the no ePLND and ePLND groups. Console time, estimated blood loss, surgery-related complications, and biochemical recurrence (BCR) rates were compared between the groups. Multivariate analysis was used to identify independent predictors of BCR.Results: The ePLND group had longer operative and console times and greater blood loss compared with the no ePLND group (P < .01). Intraoperative surgery-related complications were also more frequent in the ePLND group (P = .01); however, no significant difference was observed in postoperative surgery-related complications (P = .28). The median follow-up period was 60 months; BCR rates were not different between the groups (P = .12). However, in a sub-analysis limited to very high-risk cases, the BCR in the no ePLND group was significantly higher than in the ePLND group (P = .01). Multivariate analysis identified pathologic T stage ≥3 and lymphovascular invasion as independent predictors of BCR, whereas ePLND was not associated with BCR.Conclusions: In this study, ePLND for high- or very high-risk prostate cancer did not improve BCR. However, it may improve BCR in very high-risk prostate cancer.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1086-1092"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osteosarcoma in Japan: report from the bone and soft tissue tumor registry 2006-2022. 日本骨肉瘤：2006-2022年骨和软组织肿瘤登记报告。

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-05 DOI: 10.1093/jjco/hyaf094

Koichi Ogura, Hirotaka Kawano, Shoji Shimose, Koji Hiraoka, Akihiko Matsumine, Akira Kawai

{"title":"Osteosarcoma in Japan: report from the bone and soft tissue tumor registry 2006-2022.","authors":"Koichi Ogura, Hirotaka Kawano, Shoji Shimose, Koji Hiraoka, Akihiko Matsumine, Akira Kawai","doi":"10.1093/jjco/hyaf094","DOIUrl":"10.1093/jjco/hyaf094","url":null,"abstract":"Background: Osteosarcoma is the most common primary malignant bone tumor. Although previous studies reported genetic differences between younger and older patients, comprehensive nationwide data remain scarce. This study aimed to describe age-related differences in demographics, treatment, and survival using Japan's Bone and Soft Tissue Tumor (BSTT) Registry.Methods: We retrospectively analyzed 3446 osteosarcoma cases recorded in the BSTT Registry from 2006 to 2022. Patient demographics, tumor characteristics, treatment modalities, and outcomes were examined, with a focus on differences across age groups.Results: The cohort showed a slight male predominance (57%) and bimodal age distribution peaking at 10-19 and 70-79 years. The proportion of patients aged ≥60 years increased from 16% (2006-2012) to 19% (2013-2022). The femur (46%) was the most common tumor site, but spine or pelvis involvement was more frequent in elderly patients. Nodal and distant metastases were more common in older adults (5% vs 2%, and 26% vs 17%, respectively). Patients aged <60 underwent surgery and chemotherapy more often (79% and 83%) compared to those aged ≥60 (61% and 47%). The 5-year disease-specific survival (DSS) rate was 64% overall, but markedly lower in the elderly (40%) than younger patients (70%). Key prognostic factors included histologic grade, metastasis status, tumor size, location, and surgical margins. DSS was slightly worse in recent years, though not statistically significant (P = 0.080).Conclusions: This nationwide analysis highlights age-associated disparities in osteosarcoma care in Japan. Older patients receive less aggressive treatment and have poorer outcomes. These findings may inform healthcare planning in aging societies globally.Level of evidence: Prognostic studies, Level III.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1046-1053"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostication in advanced cancer: foreseeing from global insights and foretelling in the Asian context. 晚期癌症的预测：从全球视角预测和亚洲背景预测。

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-05 DOI: 10.1093/jjco/hyaf090

Yusuke Hiratsuka, Jun Hamano, Masanori Mori, Sang-Yeon Suh, David Hui

{"title":"Prognostication in advanced cancer: foreseeing from global insights and foretelling in the Asian context.","authors":"Yusuke Hiratsuka, Jun Hamano, Masanori Mori, Sang-Yeon Suh, David Hui","doi":"10.1093/jjco/hyaf090","DOIUrl":"10.1093/jjco/hyaf090","url":null,"abstract":"Accurate prognostic information is crucial for guiding end-of-life (EOL) decision-making in advanced cancer care. Although the European Society for Medical Oncology (ESMO) recommends using clinicians' prediction of survival (CPS) as an initial reference, CPS alone often lacks precision. This review synthesizes current prognostic models and the dialog surrounding EOL survival prediction. For patients with an expected survival of months, several validated prognostic tools are available, including measures such as the Eastern Cooperative Oncology Group Performance Status, the modified Glasgow Prognostic Scale, and comprehensive models such as the Supportive and Palliative Care Indicator Tool and the adaptable prognosis prediction model. When survival is expected to be weeks, the Palliative Performance Scale serves as a key assessment tool, while models such as the Palliative Prognostic Index and Prognosis in Palliative Care Study models are helpful. In the final days of life, clinicians primarily rely on observable physical indicators, including decreased consciousness and specific breathing patterns, whereas the surprise question has demonstrated limited predictive utility in this context. While most patients with advanced cancer express a desire for prognostic information, cultural considerations-particularly in Asia-necessitate nuanced communication approaches. Serious illness conversations have been shown to improve patient well-being; however, further research is needed to optimize these discussions, address unfinished business, and promote equitable access to prognostic dialog, particularly for vulnerable populations. Enhancing prognostic communication is critical for facilitating shared decision-making and improving the quality of EOL care.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"991-999"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic risk factors and clinical implications of adjuvant radiotherapy in T1/2 major salivary gland cancer. T1/2大涎腺癌辅助放疗的预后危险因素及临床意义。

IF 2.2 4区医学

Japanese journal of clinical oncology Pub Date : 2025-09-05 DOI: 10.1093/jjco/hyaf089

Jooin Bang, Oh-Hyeong Lee, Geun-Jeon Kim, Sang-Yeon Kim, Dong-Il Sun

{"title":"Prognostic risk factors and clinical implications of adjuvant radiotherapy in T1/2 major salivary gland cancer.","authors":"Jooin Bang, Oh-Hyeong Lee, Geun-Jeon Kim, Sang-Yeon Kim, Dong-Il Sun","doi":"10.1093/jjco/hyaf089","DOIUrl":"10.1093/jjco/hyaf089","url":null,"abstract":"Background: This study aimed to investigate the prognostic risk factors for T1/2 major salivary gland cancer. Additionally, we sought to determine the impact of adjuvant radiotherapy, especially in low-grade cancer cases with clinicopathological adverse features.Methods: A retrospective review of medical records for 93 patients who underwent surgery for T1/2 major salivary gland cancers between January 2000 and December 2024 was conducted. We evaluated clinicopathological adverse features as prognostic factors and compared 5-year disease-free survival (DFS) to determine the influence of adjuvant radiotherapy on prognosis in low-grade cancer cases exhibiting any histological adverse features.Results: Lymphatic invasion was linked to reduced 5-year overall survival in patients with T1/2 major salivary gland cancers (hazard ratio [HR] = 8.563, 95% confidence interval [CI] = 1.202-60.996, P = .032). Regarding 5-year DFS, histological grade and positive nodal metastasis were pinpointed as detrimental prognostic factors (HR = 3.330, 95% CI = 1.023-10.842, P = .046; HR = 9.891, 95% CI = 1.520-64.355, P = .046, respectively). For low-grade cancers presenting with any clinicopathological adverse features, no significant difference was observed in 5-year DFS following adjuvant radiotherapy (86.8% vs. 93.8%, P = .781).Conclusions: Lymphatic invasion, high histological grade, and positive nodal metastasis were determined as poor prognostic factors in T1/2 major salivary gland cancer. However, adjuvant radiotherapy did not significantly influence the prognosis in low-grade cancer cases with adverse features.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1022-1028"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0